Login
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc.

bbotx.com

What Do They Do?

Develops oral small-molecule cancer drug candidates for people with cancers driven by RAS and phosphoinositide kinase alpha.

How Are They Changing?

Since the FY2025 annual report
  • Apr 20, 2026 Pedro Beltran became CEO, succeeding Eli Wallace Beltran was appointed effective immediately; Wallace resigned from the board and was expected to continue as an adviser.

Who Do They Compete With?

Competes with AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Merck KGaA, Regeneron Pharmaceuticals, Sanofi Genzyme, and Roche

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support